Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 14, Number 9—September 2008

Pediatric Parapneumonic Empyema, Spain

Ignacio ObandoComments to Author , Carmen Muñoz-Almagro, Luis A. Arroyo, David Tarrago, David Sanchez-Tatay, David Moreno-Perez, Sahar S. Dhillon, Cristina Esteva, Susanna Hernandez-Bou, Juan J. Garcia-Garcia, William P. Hausdorff, and Angela B. Brueggemann
Author affiliations: Virgen del Rocio Children’s Hospital, Seville, Spain (I. Obando, L.A. Arroyo, D. Sanchez-Tatay); Sant Joan de Deu Hospital, Barcelona, Spain (C. Muñoz-Almagro, C. Esteva, S. Hernandez-Bou, J.J. Garcia-Garcia); Spanish Reference Laboratory for Pneumococci, Madrid, Spain (D. Tarrago); Carlos de Haya Children’s Hospital, Malaga, Spain (D. Moreno-Perez); University of Oxford, Oxford, UK (S.S. Dhillon, A.B. Brueggemann);; GlaxoSmithKline Biologicals, Rixensart, Belgium (W.P. Hausdorff);

Main Article

Table 1

Demographic characteristics of 208 patients with PPE enrolled during the molecular analysis study period*

Characteristic Value
Age, mo, mean ± SD (range) 51.8 ± 31 (2–180)
Gender ratio, M/F 1.06
Underlying disease, %† 4
Oral antimicrobial drugs before admission, %‡ 29
Antimicrobial drug free before thoracocentesis, %§ 23
PCV7 >1 dose, % 31
Referral, % 38

*PPE, pediatric parapneumonic empyema; PCV7, 7-valent pneumococcal conjugate vaccine.
†Underlying disease included (no. patients): lymphoma (2), congenital heart disease (2), mild psychomotor retardation (2), varicella zoster infection (2) and genetic disease (1).
‡Median duration: 3 d, range 1–17 d.
§100/147 children who had not been treated with oral antimicrobial drug therapy before admission received intravenous antimicrobial drug treatment before thoracocentesis for a median of 2 d (range 1–10 d).

Main Article

Page created: July 13, 2010
Page updated: July 13, 2010
Page reviewed: July 13, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.